• CureVac NV CVAC.OQ reported quarterly adjusted earnings of €1.50​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -22 cents. The mean expectation of six analysts for the quarter was for earnings of 56 cents per share. Wall Street expected results to range from -29 cents to €1.49 per share.

• Revenue rose 2,896.4% to $493.90 million from a year ago; analysts expected $103.76 million.

• CureVac NV's reported EPS for the quarter was €1.50​.

• The company reported quarterly net income of $338.04 million.

• CureVac NV shares had fallen by 2.0% this quarter and lost 31.6% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 2.5% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 3 "hold" and 1 "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for CureVac NV is 7.00

This summary was machine generated from LSEG data November 13 at 08:22 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)